目的：探讨芪明颗粒对非增殖期糖尿病视网膜病变(non-proliferative diabetic retinopathy，NPDR)的治疗效果及安全性评价。

方法：选择2016-01/2017-11我院内分泌科收治的非增殖期糖尿病视网膜病变患者94例120眼，运用随机数字表法分为对照组47例60眼和试验组47例60眼。对照组施以羟苯磺酸钙治疗，试验组施以芪明颗粒治疗，观察两组患者的临床治疗效果，以及治疗前与治疗6mo后的黄斑中心厚度改善情况、视网膜循环时间、最佳矫正视力恢复情况与不良反应发生情况。

结果：治疗前，两组患者的黄斑中心厚度、视网膜循环时间及视力情况，差异无统计学意义(P>0.05)； 治疗后，试验组的黄斑中心厚度明显薄于对照组，视网膜循环时间和对照组无差异，视力恢复情况明显优于对照组，且试验组治疗后的总有效率为97%，明显高于对照组(57%)，不良反应发生率显著降低，差异具有统计学意义(P<0.05)。

结论：芪明颗粒对非增殖期糖尿病视网膜病变的治疗效果优于羟苯磺酸钙，能够提升患者的视力，改善黄斑水肿情况，缩短视网膜循环时间，且不良反应发生率低。

METHODS: Totally 94 cases(120 eyes)of NPDR patients treated in endocrinology department of our hospital from January 2016 to November 2017 were selected and randomly divided into the control group(n=47, 60 eyes)and the experimental group(n=47, 60 eyes). The control group was treated with calcium dobesilate, and the experimental group was treated with Qiming granule. The clinical efficacy, central macular thickness, retinal circulation time, best corrected visual acuity and adverse reactions between two groups were evaluated and compared after 6-month treatment.

RESULTS: Before treatment, there were no significant difference in central macular thickness, retinal circulation time, and best corrected visual acuity between two groups(P>0.05). After treatment, comparing with the control group, the retinal circulation time were not significantly different, the improvement of macular edema and the recovery of visual acuity were significantly better in the experimental group. The total effective rate of the experimental group was 97%, which was significantly higher than that of the control group(57%), and the incidence of adverse reactions was significantly decreased. The difference was statistically significant(P<0.05).

CONCLUSION: The therapeutic effect of Qiming Granule on NPDR is better than that of calcium dobesilate. Qiming Granule can improve visual acuity, macular edema, the retinal circulation time with less adverse reactions.